FENC — Fennec Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $383.89m
- $342.64m
- $44.64m
Fennec Pharmaceuticals Inc expected to post earnings of 26 cents a share - Earnings Preview
Fennec Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Fennec Pharmaceuticals And Norgine Enter Into Exclusive Licensing Agreement To Commercialize Pedmarqsi In Europe, Australia, And New Zealand
Brief: FDA Issues Reminder of Non-Substitution of PEDMARK for Pediatric Patients Receiving Cisplatin
Brief: Fennec Announces Incremental $5 Million Investment From Petrichor
Brief: Fennec Pharmaceuticals Inc Files For Stock Shelf Of Up To $90 Million - SEC Filing
Brief: Fennec Pharmaceuticals Cash And Cash Equivalents Were $12.4 MLN On Sep. 30, 2023.
Fennec Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
Fennec Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Fennec Pharmaceuticals posts Q2 EPS USD -0.21
Fennec Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cenovus Energy, Compass Pathways,
U.S. STOCKS ON THE MOVE-NovoCure, Intuit, Splash Beverage
Fennec Pharma rises on European regulator's nod for hearing loss therapy
Brief: Fennec Pharmaceuticals Announces European Commission Marketing Authorization For Pedmarqsi
Fennec Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Fennec Pharmaceuticals Announces Q1 2023 Financial Results And Provides Business Update
Fennec Pharmaceuticals Inc expected to post a loss of 21 cents a share - Earnings Preview
Fennec Pharmaceuticals rises on EU regulator backing for hearing loss therapy